Trulieve NYSE Listing Breaks US Cannabis Industry Barrier
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
trulievecannabis-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Trulieve Cannabis Corp. will list its common stock on the New York Stock Exchange on June 5, 2026, becoming the first U.S. plant-touching cannabis operator to achieve a primary listing on a major national exchange. The company announced the uplisting from the Canadian Securities Exchange, where it currently trades under the ticker TRUL. This landmark event follows the U.S. Drug Enforcement Administration's proposed rescheduling of cannabis to Schedule III in May 2026, which removed a primary regulatory barrier for exchange listings. Trulieve's market capitalization stood at $2.1 billion prior to the announcement.
The DEA's proposal to move cannabis from Schedule I to Schedule III on May 1, 2026, created the necessary regulatory clarity for national exchanges to list plant-touching companies. Schedule I designation had previously forced U.S. multi-state operators to list on Canadian exchanges or the U.S. over-the-counter markets. The last major regulatory shift for the sector occurred in 2018 when Canada federally legalized adult-use cannabis, enabling listings on the Toronto Stock Exchange.
Current macro conditions include the S&P 500 trading near all-time highs and the 10-year Treasury yield at 4.3%. This environment favors growth-oriented sectors seeking expanded investor bases. The rescheduling process accelerated following the Department of Health and Human Services recommendation in August 2023, which concluded cannabis has accepted medical use and a lower potential for abuse than Schedule I substances.
The catalyst chain began with the 2022 directive from President Biden for federal agencies to review cannabis scheduling. This led to the HHS recommendation and the DEA's subsequent proposal. This regulatory shift directly enabled the NYSE to approve Trulieve's listing application, which was contingent on federal rescheduling.
Trulieve reported $1.3 billion in revenue for fiscal year 2025, representing 12% year-over-year growth. The company operates 189 retail dispensaries across 11 states, with a particularly strong presence in Florida where it holds 40% market share. Gross margins for the last quarter were 58%, above the sector average of 50%.
| Metric | Before NYSE Listing | After NYSE Listing |
|---|---|---|
| Average Daily Volume | 1.2 million shares | Projected 3.5+ million shares |
| Institutional Ownership | ~15% | Projected 25-30% |
| Analyst Coverage | 8 firms | Projected 12-15 firms |
The AdvisorShares Pure US Cannabis ETF (MSOS), which holds Trulieve as a top weighting, saw assets under management increase by $200 million in the week following the DEA announcement. Trulieve's valuation multiple of 12x forward EBITDA compares to consumer staples at 15x and the S&P 500 at 18x.
Second-order effects include immediate benefits for other U.S. multi-state operators likely to pursue similar listings. Curaleaf (CURLF) and Green Thumb Industries (GTBIF) could see 15-20% valuation re-ratings as institutional liquidity improves across the sector. Ancillary businesses including packaging company KushCo Holdings (KSHB) and software provider Akerna (KERN) may benefit from increased sector legitimacy.
Exchange-traded funds like MSOS will experience significant structural changes as their holdings transition from OTC to NYSE listings, reducing tracking error and potentially lowering expense ratios. Banking sector exposure increases as well, with regional banks like Customers Bancorp (CUBI) likely to expand cannabis banking services.
The primary counter-argument concerns remaining regulatory uncertainty. Rescheduling to Schedule III maintains federal illegality while creating a more favorable tax structure under IRS Code 280E. Full descheduling would require congressional action, which remains unlikely in the current political environment.
Institutional flow data shows hedge funds and long-only asset managers building positions in anticipation of the listing. Short interest in Trulieve decreased by 30% in the month preceding the announcement as regulatory risk diminished.
The DEA's final rule on rescheduling is expected by August 30, 2026, following a public comment period. This decision will determine whether other operators can follow Trulieve's path to national exchanges. Congressional banking reform, specifically the SAFER Banking Act, faces a Senate vote before the August recess.
Technical levels to watch include Trulieve's $25 share price, which represents a key resistance level that, if broken, could target the $30-32 range. Sector ETF MSOS faces resistance at the $12.50 level, which corresponds to its 2024 high.
Earnings on August 15, 2026, will provide the first post-listing financial results and guidance. Analyst expectations project 15% revenue growth for fiscal 2026, with margin expansion to 60% as 280E tax burdens decrease.
Retail investors gain access to a previously hard-to-trade security through standard brokerage accounts without needing to enable OTC trading. The listing eliminates the bid-ask spread penalty typically associated with OTC stocks, which often ranged from 2-5% for cannabis names. This significantly reduces transaction costs for individual investors while providing improved liquidity and transparency in pricing.
Canadian companies like Canopy Growth and Tilray listed on major U.S. exchanges through reverse mergers or direct listings but operated under full federal legalization. Trulieve's listing represents a breakthrough for U.S. operators working under continuing federal prohibition despite state-level legalization. The market structure difference means U.S. companies will trade alongside mainstream equities rather than as a separate sector category.
Schedule III classification allows U.S. cannabis companies to deduct ordinary business expenses under IRS Code 280E, which previously prohibited deductions for businesses trafficking controlled substances. This changes effective tax rates from 70-80% to standard corporate rates of 21-28%, potentially increasing net income by 40-50% for profitable operators. The change applies retroactively to open tax years, creating potential tax refund opportunities for companies with existing operations.
Trulieve's NYSE listing marks the single largest step toward cannabis normalization in U.S. financial markets.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.